Study Finds Widespread Misleading Online Ads for Unapproved Drugs
A new analysis reveals that many online pharmacies use misleading claims and omit key safety data when advertising non-FDA-approved compounded drugs, increasing regulatory risk.
A law firm analysis of online vendors found widespread promotion of non-FDA-approved drugs using potentially misleading claims and inadequate safety disclosures. The study focused on telehealth platforms and online pharmacies advertising compounded treatments for obesity, erectile dysfunction, and hair loss. Researchers found that vendors often promote novel formulations and multi-drug combinations that have not been evaluated by the FDA for safety or efficacy. Marketers also frequently reference well-known brand-name drugs to suggest their compounded products are equivalent, potentially confusing consumers.
Sophisticated clients and counsel should care because the FDA has significantly increased enforcement, issuing over 100 warning letters to telehealth providers and pharmacies since September 2025. This signals a heightened risk for companies in the drug supply and advertising chain. The report notes that while the FDA's "Bad Ad Program" helps monitor approved drugs, a potential gap exists for unapproved ones, an area the agency may target next. Companies should review their marketing and disclosure practices for all drug products to mitigate regulatory and litigation risk.